Edgewise Therapeutics, Inc.
EWTX
Clasificación en acciones
#4051
Edgewise Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing... Edgewise Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing small-molecule treatments for a range of musculoskeletal disorders. Its leading investigational drug, EDG-5506, is an orally administered compound specifically engineered to tackle the fundamental genetic causes of dystrophinopathies, including Duchenne and Becker muscular dystrophy. This candidate has successfully concluded its Phase 1 clinical trial. Beyond EDG-5506, Edgewise maintains a pipeline of precision medicine candidates designed to modulate key muscle proteins, thereby addressing various genetically defined muscle conditions. Established in 2017, the company is headquartered in Boulder, Colorado.
Precio por acción
$37.15
Última sincronización: 2026-10-16
Capitalización bursátil
$4.00B
Cambio (1 día)
-2.75%
Cambio (1 año)
146.68%
País
US
Comercio Edgewise Therapeutics, Inc. (EWTX)
Categoría
Healthcare
EPS de Edgewise Therapeutics, Inc. (EWTX)
EPS a fecha de June 2026 TTM: $-1.85
Según los últimos informes financieros y el precio de las acciones de Edgewise Therapeutics, Inc., el EPS actual de la empresa (TTM) es $-1.85. Al final del año 2023, la empresa tenía un EPS de $-1.57 un aumento con respecto a al EPS de 2022, que fue de $-1.26.
Historial de EPS de Edgewise Therapeutics, Inc. desde 2019 hasta 2026
EPS al final de cada año
| Año | EPS | Cambiar |
|---|---|---|
| 2026 (TTM) | $-1.85 | 27.59% |
| 2024 | $-1.45 | -7.64% |
| 2023 | $-1.57 | 24.60% |
| 2022 | $-1.26 | 46.51% |
| 2021 | $-0.86 | 145.71% |
| 2020 | $-0.35 | 84.21% |
| 2019 | $-0.19 | 0.00% |
EPS de empresas similares o competidoras
| Empresa | EPS | Diferencia de EPS | País |
|---|---|---|---|
| $17.32 | -1,036.22% |
US
|
|
| $-7.98 | 331.35% |
US
|
|
| $-5.29 | 185.95% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -1,599.46% |
NL
|
